Menu Search
Equities

Stem Cells Spin SA

SCS:WSE

Stem Cells Spin SA

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (PLN)0.214
  • Today's Change-0.024 / -10.08%
  • Shares traded25.15k
  • 1 Year change-46.77%
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in PLNIncome statement in PLNView more

Year on year Stem Cells Spin SA had net income fall from a gain of 26.61k to a loss of 154.35k despite a 68.84% increase in revenues from 248.36k to 419.32k. An increase in the cost of goods sold as a percentage of sales from 8.25% to 10.64% was a component in the falling net income despite rising revenues.
Gross margin80.24%
Net profit margin-157.95%
Operating margin-156.29%
Return on assets-2.58%
Return on equity-4.81%
Return on investment-4.18%
More ▼

Cash flow in PLNView more

In 2023, cash reserves at Stem Cells Spin SA fell by 55.62k. However, the company earned 341.20k from its operations for a Cash Flow Margin of 81.37%. In addition the company used 247.46k on investing activities and also paid 149.36k in financing cash flows.
Cash flow per share0.0182
Price/Cash flow per share11.74
Book value per share0.1734
Tangible book value per share0.0669
More ▼

Balance sheet in PLNView more

Stem Cells Spin SA uses little debt in its capital structure as supported by a debt to capital ratio of 0.74%.
Current ratio0.1338
Quick ratio0.0118
Total debt/total equity0.0075
Total debt/total capital0.0074
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.